Search clinical trials for: Breezhaler

Total 24 results

Novartis Pharmaceuticals

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Asthma

Italy, Spain, Austria, Portugal, Argentina, South Africa, Greece, Hungary, Colombia, Mexico, Guatemala, Romania, Czechia
Novartis Pharmaceuticals

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Asthma

Spain, Hungary, United Kingdom, South Africa, Colombia, Guatemala, Bulgaria, Poland
Novartis Pharmaceuticals

Completed

Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (ADITION)

Asthma

Germany
GlaxoSmithKline

Completed

A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

Asthma

Netherlands
Università degli Studi di Ferrara

Terminated

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Italy
Orion Corporation, Orion Pharma

Completed

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (FORELLI)

Healthy Volunteers

Finland
Novartis Pharmaceuticals

Withdrawn

An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma (SENSE)

Asthma
University Hospital, Bordeaux

Completed

Description of the Ability to Learn How to Handle Inhaler Devices in COPD (INTUITIVE)

Chronic Obstructive Pulmonary Disease (COPD)

France
Chiesi Farmaceutici S.p.A.

Completed

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Novartis Pharmaceuticals

Terminated

A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence (ADVICE)

Chronic Obstructive Pulmonary Disease

Germany, Netherlands
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Novartis Pharmaceuticals

Completed

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (Advantage)

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Wouter H. van Geffen
Novartis; University Medical Center Groningen

Completed

Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD (ULT01)

COPD

Netherlands
GlaxoSmithKline

Completed

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
Almirall, S.A.
Forest Laboratories

Completed

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Preference Tiotropium Respimat Study in COPD

Pulmonary Disease, Chronic Obstructive

Spain
University of Milan
Fondazione Salvatore Maugeri

Completed

Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients

Hyperinflation | COPD | Right Cardiac Failure

Italy
University of Milan
Fondazione Salvatore Maugeri

Completed

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Chronic Obstructive Pulmonary Disease

Italy
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil

3

Subscribe